

Bölüm 7

MYELOM BÖBREĞİ PATO FİZYOLOJİSİ

Sinan KAZAN¹

GİRİŞ

Multiple myelomada(MM) böbrek birçok şekilde etkilenebilir (Sanders & ark., 1991, Sanders, 1994, Winearls, 1995, Cohen & ark., 1984, Haynes & ark., 2010, Bladé & ark.,1998). MM'deki farklı böbrek patolojileri farklı klinik tablo, tedavi ve prognoza sahiptir (Leung & Behrens, 2012). Bu nedenle, böbrek yetmezliği olan bir MM hastasını değerlendirirken MM'de böbrek hastalıklarının patofizyolojisini bilmek önemlidir. MM'de böbrek hastalığı genellikle plazma hücrelerinden monoklonal immünglobulin veya immünglobulin fragmanları üretimine bağlıdır. MM'de akut böbrek hasarı (ABH) için en sık görülen histolojik tanı myelom Cast nefropatisi (MCN) ve akut tübüler nekrozdur(ATN) (Leung & ark., 2008). Şiddetli ABH'sı olan hastaları değerlendiren başka bir çalışmada MCN en yaygın böbrek histopatolojisi olarak bulunmuştur (Rota & ark., 1987). Yapılan diğer çalışmalarda ise MCN, ATN, AL amiloidoz, monoklonal immünglobulin birikim hastalığı, hafif zincir fanconi hastalığı, membranoproliferatif glomerülonefrit, immünotaktoid glomerülonefrit, renal öneme sahip monoklonal gammopati ve myeloma infiltrasyonunun çeşitli oranlarda myelom hastalarında böbrek tutulumuna neden olabileceği gösterilmiştir (Ivanyi, 1990, Kapadia, 1980, Oshima & ark., 2001, Nasr & ark., 2012a, Solomon & ark., 1991, Leung & ark., 2012). Myelomdaki bu böbrek tutulumları klinikte kendilerini farklı şekillerde gösterebilmektedir. Bu bölümde monoklonal proteinlerin hasar mekanizmaları anlatıldıktan sonra klinik prezentasyon şekillerine göre böbrek hastalığı fizyopatolojileri ele alınacaktır.

¹ Dr. Sinan Kazan, Afyon Sağlık Bilimleri Üniversitesi Hastanesi, sinankazan@hotmail.com

Elektrolit anormallikleri

Hafif zincir proksimal tübülopatisi

Bazı hastalarda hafif zincirler, glomerüler filtrasyon hızında bir azalma olmadan sadece tübül disfonksiyonuna neden olur. Proksimal tübül bu durumdan en fazla etkilenen tübül parçasıdır (Sanders & ark., 1988a). Bu lezyonu üreten hafif zincirlerin, tübüler hücrelerde lizozomlardaki proteazlar tarafından bozulmalara karşı dirençli kılan eşsiz biyokimyasal özelliklere sahip değişken bir alana sahip oldukları görülmektedir (Leboulleux & ark., 1995). Tübüler fonksiyon bozukluğundan muhtemelen değişken alan fragmanlarının sonradan hücre içi kristal formasyonu ile birikmesi sorumludur (Decourt & ark., 1999). Proksimal tübülopatiyeye sebep olan hafif zincirlerin yaklaşık yüzde 90'ı kapp hafif zincirlerinden oluşmaktadır (Ma & ark., 2004).

Proksimal tübüler fonksiyon bozukluğu ayrıca hafif zincir reabsorbsiyonunu azaltarak hafif zincir Cast nefropatisini şiddetlendirebilir. Bir vaka serisinde 46 hastanın %38'inde Fanconi sendromu olduğu raporlanmıştır (Stokes & ark., 2016).

Sonuç

MM'de böbrek tutulumu olması prognostik bir gösterge olarak bilinmektedir. Myelom hastasında böbrek tutulumunun tipini ve tedavisini iyi bilmek hastalığın patofizyolojisine hakim olmayı gerektirir. Bu bölümde MM hastasında böbrek tutulum mekanizmaları ve klinik prezentasyona göre patofizyolojik mekanizmalar anlatılmıştır

Anahtar Kelimeler: böbrek, fizyopatoloji, multiple myelom, proteinüri

KAYNAKÇA

- Akilesh S, Alem A & Nicosia RF. Combined crystalline podocytopathy and tubulopathy associated with multiple myeloma. *Hum Pathol* 2014; 45:875.
- Alpers CE & Cotran RS. Neoplasia and glomerular injury. *Kidney Int* 1986; 30:465.
- Arimura A, Li M & Batuman V. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. *Blood* 2006; 107:661.
- Benabe JE & Martinez-Maldonado M. Hypercalcemic nephropathy. *Arch Intern Med* 1978; 138:777.
- Bhutani G & et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. *Mayo Clin Proc* 2015; 90:587.
- Bladé J & et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. *Arch Intern Med* 1998; 158:1889.
- Bourke E & et al. Hypocomplementemic proliferative glomerulonephritis with C3 nephritic-factor-like activity in multiple myeloma. *Nephron* 1989; 52:231.
- Bridoux F & et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? *Clin J Am Soc Nephrol* 2011; 6:2165.
- Carstens PH % Woo D. Crystalline glomerular inclusions in multiple myeloma. *Am J Kidney Dis* 1989; 14:56.

- Cohen DJ & et al. Acute renal failure in patients with multiple myeloma. *Am J Med* 1984; 76:247.
- Cohen HJ & Rundles RW. Managing the complications of plasma cell myeloma. *Arch Intern Med* 1975; 135:177.
- Decourt C, & et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. *Blood* 1999; 94:3559.
- DeFronzo RA & et al. Renal function in patients with multiple myeloma. *Medicine (Baltimore)* 1978; 57:151.
- Dimopoulos MA & et al. Pathogenesis and treatment of renal failure in multiple myeloma. *Leukemia* 2008; 22:1485.
- Fattori E & et al. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. *Blood* 1994; 83:2570.
- Fogo A, Qureshi N & Horn RG. Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. *Am J Kidney Dis* 1993; 22:367.
- Gu X & Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. *Arch Pathol Lab Med* 2006; 130:165.
- Haynes RJ & et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. *Nephrol Dial Transplant* 2010; 25:419.
- Hobeika L, Self SE & Velez JC. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. *BMC Nephrol* 2014; 15:156.
- Holland MD & et al. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. *Kidney Int* 1985; 27:46.
- Huang ZQ & Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. *J Clin Invest* 1997; 99:732.
- Ivanyi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. *Arch Pathol Lab Med.* 1990;114(9):986-987.
- Iványi B. Renal complications in multiple myeloma. *Acta Morphol Hung* 1989; 37:235.
- Jeon YL & et al. Crystalloid podocytopathy with focal segmental glomerulosclerosis in PCM: a case report. *Diagn Pathol* 2015; 10:213.
- Kapadia SB. Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. *Medicine.* 1980;59(5):380-392.
- Kyle RA & Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia* 2009; 23:3.
- Leboulleux M & et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. *Kidney Int* 1995; 48:72.
- Leung N & Behrens J. Current approach to diagnosis and management of acute renal failure in myeloma patients. *Adv Chronic Kidney Dis.* 2012;19(5):297-302.
- Leung N & et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. *Blood.* 2012;120(22):4292-4295.
- Leung N & et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. *Kidney Int.* 2008;73(11):1282- 1288.
- Lin J & et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. *J Am Soc Nephrol* 2001; 12:1482.
- Lodhi A & et al. Thrombotic microangiopathy associated with proteasome inhibitors. *Clin Kidney J* 2015; 8:632.
- Ma CX & et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. *Blood* 2004; 104:40.
- Markowitz GS & et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. *J Am Soc Nephrol* 2001; 12:1164.
- Markowitz GS & et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). *Kidney Int* 2003; 64:281.

- McCarthy CS & Becker JA. Multiple myeloma and contrast media. *Radiology* 1992; 183:519.
- Montseny JJ & et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. *Nephrol Dial Transplant* 1998; 13:1438.
- Morgan C Jr & Hammack WJ. Intravenous urography in multiple myeloma. *N Engl J Med* 1966; 275:77.
- Nasr SH & et al. Dysproteinemia, proteinuria, and glomerulonephritis. *Kidney Int* 2006; 69:772.
- Nasr SH & et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. *Kidney Int* 2004; 65:85.
- Nasr SH & et al. Proliferative glomerulonephritis with monoclonal IgG deposits. *J Am Soc Nephrol* 2009; 20:2055.
- Nasr SH & et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. *Clin J Am Soc Nephrol* 2011; 6:775.
- Nasr SH & et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. *Clin J Am Soc Nephrol* 2012a; 7:231.
- Nasr SH & et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. *Am J Kidney Dis*. 2012b;59(6):786-794.
- Oshima K & et al. Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. *Am J Hematol*. 2001;67(1):1-5.
- Pasquali S & et al. Renal histological lesions and clinical syndromes in multiple myeloma. *Renal Immunopathology Group. Clin Nephrol* 1987; 27:222.
- Pirani CL & et al. Renal lesions in plasma cell dyscrasias: ultrastructural observations. *Am J Kidney Dis* 1987; 10:208.
- Rota S & et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. *Medicine*. 1987;66(2):126-137.
- Said SM & et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. *Clin J Am Soc Nephrol* 2013; 8:1515.
- Sakhuja V & et al. Renal involvement in multiple myeloma: a 10-year study. *Ren Fail* 2000; 22:465.
- Sanders PW & et al. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. *J Clin Invest* 1990; 85:570.
- Sanders PW & Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. *J Clin Invest* 1992; 89:630.
- Sanders PW & et al. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. *J Clin Invest* 1988a; 82:2086.
- Sanders PW & et al. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypic immunoglobulin light chain deposition. *Lab Invest* 1991; 64:527.
- Sanders PW & et al. Morphologic alterations of the proximal tubules in light chain-related renal disease. *Kidney Int* 1988b; 33:881.
- Sanders PW. Mechanisms of light chain injury along the tubular nephron. *J Am Soc Nephrol* 2012; 23:1777.
- Sanders PW. Pathogenesis and treatment of myeloma kidney. *J Lab Clin Med* 1994; 124:484.
- Sengul S, Zwizinski C & Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. *Am J Physiol Renal Physiol* 2003; 284:F1245.
- Sengul S & et al. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. *Kidney Int* 2002; 62:1977.
- Sepandj F & Trillo A. Dense deposit disease in association with monoclonal gammopathy of unknown significance. *Nephrol Dial Transplant* 1996; 11:2309.
- Sethi S & et al. Crystal-storing histiocytosis involving the kidney in a low-grade B-cell lymphoproliferative disorder. *Am J Kidney Dis* 2002; 39:183.
- Sethi S & Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. *N Engl J Med* 2012; 366:1119.
- Sethi S & et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. *Clin J Am Soc Nephrol* 2010; 5:770.

- Smolens P, Barnes JL & Kreisberg R. Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins. *J Lab Clin Med* 1987; 110:460.
- Solomon A, Weiss DT & Kattine AA. Nephrotoxic potential of Bence Jones proteins. *New Engl J Med*. 1991;324(26):1845-1851.
- Stokes MB & et al. Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. *J Am Soc Nephrol* 2016; 27:1555.
- Wanchoo R & et al. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. *Clin J Am Soc Nephrol* 2017; 12:176.
- Wang PX & Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. *J Am Soc Nephrol* 2007; 18:1239.
- Winearls CG. Acute myeloma kidney. *Kidney Int* 1995; 48:1347.
- Yamamoto T & et al. Crystal-storing histiocytosis and crystalline tissue deposition in multiple myeloma. *Arch Pathol Lab Med* 1991; 115:351.
- Ying WZ & et al. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. *J Clin Invest* 2012; 122:1777.
- Ying WZ & et al. Immunoglobulin light chains activate nuclear factor- κ B in renal epithelial cells through a Src-dependent mechanism. *Blood* 2011; 117:1301.
- Zand L & et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. *Am J Kidney Dis* 2013; 62:506.